Multiple Factors Suggest Genzyme Still Faces Problems Related To Cerezyme

The biotech's decontaminated plant has reopened, but FDA plans to re-inspect the facility. In addition, Genzyme had to discard more in-process Cerezyme than expected and a competitor's investigational drug has received clearance for emergency use by FDA.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet